NASDAQ:CRSP
CRISPR Therapeutics Stock News
$56.22
+0.550 (+0.99%)
At Close: May 17, 2024
CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag
09:11am, Thursday, 04'th Nov 2021
CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
06:22pm, Wednesday, 03'rd Nov 2021
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1.18% and -78.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 02'nd Nov 2021
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser
3 Things About CRISPR Therapeutics That Smart Investors Know
06:10am, Wednesday, 20'th Oct 2021
The company's value isn't reflected in typical performance metrics.
Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More
03:18pm, Tuesday, 19'th Oct 2021
Another day of strong earnings is pushing the broad markets higher across the board.
2 Top Healthcare Stocks That Could Be Bought Out in 2022
07:00am, Saturday, 16'th Oct 2021
These two novel-drug makers could be top takeover targets next year.
Crispr Therapeutics: The Future Of Gene Therapy
03:27am, Friday, 15'th Oct 2021
CRISPR Therapeutics was down at one point 10% after hours following reports of poorer than expected efficacy levels for its CTX110 CAR-T cell therapy. CRISPR is currently (55%) off all-time highs set
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
12:38pm, Thursday, 14'th Oct 2021
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Cathie Wood's ARK Invest Buys Over 675,000 More Shares of CRISPR
09:41am, Thursday, 14'th Oct 2021
A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday.
CRISPR Therapeutics Announces Transition of Chief Financial Officer
07:00am, Thursday, 14'th Oct 2021
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser
CRISPR price outlook: RBC sees upside to $117
03:04pm, Wednesday, 13'th Oct 2021
Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) fell just under 10% on Wednesday as the biotech firm presented updated data for the phase 1 trial of its blood cancer candidate CTX 110. RBC Capital m
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today
12:31pm, Wednesday, 13'th Oct 2021
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lowe
Why CRISPR Therapeutics Stock Is Sinking Today
10:52am, Wednesday, 13'th Oct 2021
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
Why CRISPR Therapeutics Stock Is Tumbling Today
09:01am, Wednesday, 13'th Oct 2021
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies. “We
Will CRISPR Stock Rebound After A 17% Fall In A Month?
09:00am, Wednesday, 13'th Oct 2021
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year bef
